USPTO Examiner JUSTICE GINA CHIEUN YU - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19172483CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITISApril 2025July 2025Allow300NoNo
19075217MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2025August 2025Allow510NoNo
18909566DERMAL PATCH AND SYSTEMS, KITS, AND METHODS ASSOCIATED THEREWITHOctober 2024August 2025Allow1020NoNo
18900544METHODS OF INSECT CONTROL FOR AN ANIMAL, PRODUCTS THEREOF AND METHODS FOR THEIR PREPARATIONSeptember 2024July 2025Allow1010NoNo
18898561ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGELSeptember 2024December 2024Allow200NoNo
18725024COMPOSITION AND METHOD OF INDUCING SYSTEMIC ACQUIRED RESISTANCE (SAR) IN PLANTSJune 2024March 2026Allow2010YesNo
18720721EFFECT PIGMENTS HAVING A REFLECTIVE CORE AND SEMICONDUCTOR LAYERSJune 2024March 2025Allow910NoNo
18732895Method of Treating Oxidative Stress in Skin and Compositions ThereforJune 2024January 2026Allow1921YesNo
18668674CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDEMay 2024November 2025Abandon1811NoNo
18650542FORMULATIONS OF AG10April 2024September 2025Allow1610YesNo
18630275SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTApril 2024December 2025Allow2020NoNo
18621501ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTMarch 2024August 2025Allow1711NoNo
18593225MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2024February 2025Allow1110YesNo
18445785Microdaily EMF Protects Against Oxidative and Inflammatory Damage, and Acute and Late Adverse Effects of EMF RadiationFebruary 2024August 2025Allow1930YesNo
18539823OPHTHALMIC COMPOSITIONDecember 2023January 2026Allow2520NoNo
18487938TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATIONOctober 2023February 2026Allow2810NoNo
18474052MINOXIDIL ADJUVANT THERAPIESSeptember 2023April 2025Abandon1810NoNo
18467858TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONSeptember 2023December 2024Allow1510NoNo
18244628PHARMACEUTICAL COMPOSITIONSeptember 2023February 2026Allow3040NoNo
18456625SKIN CARE COMPOSITIONAugust 2023August 2024Allow1110NoNo
18233853GANCICLOVIR COMPOSITIONS AND RELATED METHODSAugust 2023December 2024Abandon1610NoNo
18366907Hemp Oil/Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and lnflammationAugust 2023December 2024Abandon1610NoNo
18218954COMPOSITION AND METHOD OF TREATING CONDITIONS ASSOCIATED WITH EXTRACELLULAR MATRIX DYSFUNCTION BY ADMINISTERING MICRONUTRIENT COMPOSITIONJuly 2023April 2024Allow1020YesNo
18196617ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTMay 2023August 2023Allow310NoNo
18315891CELLULOSE SCAFFOLDS DERIVED FROM MACROALGAE, PROCESS FOR THE PREPARATION THEREOF AND USES THEREOFMay 2023March 2026Abandon3401NoNo
18112781pH TRIGGERED RELEASE PARTICLEFebruary 2023March 2024Allow1320NoNo
18110079Embossed Effect Pigment and Method of Manufacture of Embossed Effect PigmentFebruary 2023May 2024Allow1510NoNo
18163818EXTENDED RELEASE AMPHETAMINE TABLETSFebruary 2023April 2024Allow1510NoNo
18075863TOPICAL MUSCLE RELAXATION COMPOSITIONS AND METHODSDecember 2022March 2024Allow1620YesNo
18008191ULTRASONIC PREPARATION METHOD OF PROTEIN-DERIVED PEPTIDE-POLYSACCHARIDE NANOPARTICLES LOADED WITH BIOACTIVE COMPONENTSDecember 2022September 2024Abandon2210NoNo
17928993LIQUID OPHTHALMIC COMPOSITION COMPRISING A SPIRULINA PLATENSIS FULL EXTRACTDecember 2022January 2026Abandon3801NoNo
17928181GINGER WATER COMPOSITION HAVING GINGER EXTRACT AND METHOD FOR MANUFACTURING THE SAMENovember 2022June 2023Allow600NoNo
18000019ANTIVIRAL AGENT FOR PREVENTING OR TREATING COVID-19November 2022December 2025Abandon3601NoNo
17926940EDIBLE FUNGINovember 2022September 2025Abandon3401NoNo
18055940OPHTHALMIC COMPOSITIONNovember 2022August 2023Allow910NoNo
18055949OPHTHALMIC COMPOSITIONNovember 2022October 2023Allow1110NoNo
18055945OPHTHALMIC COMPOSITIONNovember 2022October 2023Allow1110NoNo
17946621IMPLANTABLE MEDICAL DEVICES FOR EXTENDED RELEASE OF THERAPEUTIC AGENTSSeptember 2022November 2025Allow3810NoNo
17896474ADHESION-PREVENTING COMPOSITIONAugust 2022September 2023Allow1310NoNo
17890122Shear-Thinning Cosmetic CompositionAugust 2022September 2023Allow1310NoNo
17820003SETTABLE SURGICAL IMPLANTS AND THEIR PACKAGINGAugust 2022May 2025Allow3320NoNo
17819159TOPICAL SKIN TREATMENT COMPOSITIONAugust 2022July 2024Abandon2310NoNo
17879797ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND HEALINGAugust 2022March 2024Allow1910NoNo
17875236FOAMING CLEANSERJuly 2022July 2024Allow2330YesNo
17794178PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACIDJuly 2022January 2026Allow4210NoNo
17794072Alginate Based Particles as a Temporary Embolic AgentJuly 2022April 2024Allow2110YesNo
17793640TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITIONJuly 2022September 2025Allow3801YesNo
17861658BIOLOGICAL PESTICIDE FUNGUS EFFECTIVE AGAINST MULTIPLE DIFFERENT SPECIES OF INSECTJuly 2022June 2024Allow2321YesNo
17841284GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMSJune 2022December 2023Allow1810NoNo
17830039METHOD AND COMPOSITION FOR REJUVENATION OF MUSCLE CELLSJune 2022April 2024Abandon2310NoNo
17780789COMPOSITIONS AND METHODS FOR BIOREMEDIATION OF GLYPHOSATE CONTAINING SUBSTRATESMay 2022May 2025Allow3600NoNo
17742960DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAMEMay 2022January 2023Allow810NoNo
17773635TEBUCONAZOLE FORMULATIONSMay 2022October 2025Abandon4220NoNo
17772728ANTI-AGING CHINESE HERB EXTRACT,EXTRACTION METHOD AND USE THEREOFApril 2022March 2025Allow3411YesNo
17659185SUPPLEMENT FOR MITIGATING WOMAN'S DISORDERS CAUSED BY AGEINGApril 2022February 2024Allow2220NoNo
17754891METHOD FOR PREPARING AN INVERSE EMULSION COMPRISING TWO CATIONIC POLYMERSApril 2022February 2023Allow1000NoNo
17767194METHOD OF PREPARING A COSMETIC COMPONENTApril 2022June 2024Allow2700NoNo
17707507Personalized Nutritional Supplements and Methods of MakingMarch 2022February 2024Allow2350YesNo
17763404COMPOSITION OF A RHEOLOGY MODIFIER AND DIHALOHYDANTOINMarch 2022October 2025Abandon4320NoNo
17699200CURCUMIN COMPOUND COMPOSITION AND METHOD FOR PREPARAING SAMEMarch 2022September 2025Abandon4202NoNo
17655470TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONMarch 2022June 2023Allow1510NoNo
17689856METHOD AND USE OF COMPOSITIONS COMPRISING LIGNOSULFONATE FOR ATTENUATION OF SARS-CoV-2 VIRUS REPLICATIONMarch 2022July 2025Allow4021NoNo
17640451USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANAMarch 2022April 2025Abandon3711NoNo
17685666FOOD SUPPLEMENT FOR ORAL ADMINISTRATIONMarch 2022May 2024Abandon2610NoNo
17681640SOLUBLE LIQUID COMPOSITIONS OF SAFLUFENACIL, METHOD OF PREPARATION AND USE THEREOFFebruary 2022October 2025Allow4311YesNo
17678178CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDEFebruary 2022September 2023Allow1820YesNo
17669442SHAPE MEMORY ADHESIVE MATERIALS FOR DIABETIC WOUND HEALINGFebruary 2022August 2025Allow4210YesNo
17669136Composition and Method Containing Pea and Quinoa Natural Peptides And Niacinamide to Enhance Skin Glow, Radiance And Even Skin ToneFebruary 2022October 2025Abandon4441YesNo
17586414COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEIJanuary 2022April 2022Allow300NoNo
17582237SKIN CARE SERUM CONTAINING SODIUM HYALURONATEJanuary 2022April 2024Abandon2720NoNo
17627926PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, CONTAINING BENTONITE AS ACTIVE INGREDIENTJanuary 2022June 2024Abandon2950NoNo
17577479FORMULATIONS OF AG10January 2022February 2024Allow2420NoNo
17576114EXTENDED RELEASE AMPHETAMINE TABLETSJanuary 2022June 2025Allow4120NoNo
17559580METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSINGDecember 2021October 2023Abandon2101NoNo
17559068CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITISDecember 2021August 2024Allow3220NoNo
17622082PINE OIL-BASED HERBICIDEDecember 2021February 2026Allow5021NoNo
17556896INTERNAL TEAT SEALANTS AND THEIR USE IN THE PREVENTION OF BOVINE MASTITIS IN THE DRY COWBDecember 2021August 2023Abandon2010NoNo
17620215COMPOSITION AND METHOD FOR IMPROVING PLANT GROWTHDecember 2021January 2026Allow4911NoNo
17618888LIQUID FORMULATION TO TREAT A CORNEAL TISSUEDecember 2021September 2025Allow4511YesNo
17549943POLYACRYLONITRILE BASED ELECTROSPUN NANOFIBERS LOADED WITH ZINC OXIDE- QUERCETIN NANOPARTICLES FOR WOUND HEALINGDecember 2021September 2025Abandon4620NoNo
17549980Method of Treating Oxidative Stress in Skin and Compositions ThereforDecember 2021February 2024Allow2621NoNo
17545178THERAPEUTIC SYSTEMS, DEVICES, AND COMPOSITIONS WITH WOUND HEALING AND TISSUE REGENERATIVE PROPERTIES, USES THEREOF, AND CORRESPONDING METHODSDecember 2021January 2024Allow2551YesNo
17613390LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING CITRATE AND CARNITINENovember 2021February 2026Allow5030NoNo
17530027COMPOSITIONS OF MIDODRINE AND METHODS OF USING THE SAMENovember 2021December 2023Allow2511NoNo
17527377OILY SOLID COSMETIC, METHOD FOR PRODUCING THE OILY SOLID COSMETIC, AND METHOD FOR PRODUCING MOLDED PRODUCT USING THE OILY SOLID COSMETICNovember 2021December 2023Abandon2511NoNo
17610500MICROPARTICLE COMPOSITIONS COMPRISING SAFLUFENACILNovember 2021April 2025Allow4110NoNo
17609955HERBICIDAL COMPOSITIONNovember 2021June 2024Allow3200NoNo
17606402COMPOUND COMPRISING A FUNCTIONAL AGENT, AND RELATED MANUFACTURING METHODOctober 2021June 2025Allow4311NoNo
17508908Herbicide Compatibility ImprovementOctober 2021July 2025Allow4402NoNo
17605104COMBINATION OF MODIFIED STARCH/C13-C15 FATTY ACID/CLAYOctober 2021September 2024Allow3511YesNo
17504087ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTOctober 2021December 2023Allow2611NoNo
17602822STABILIZATION OF SUSPENSION CONCENTRATES BY ETHOXYLATED RICINOLEINOctober 2021August 2025Allow4611NoNo
17600913TWO-COMPONENT SYSTEM FOR THE THERAPEUTIC TREATMENT OF SKIN LESIONS AND PRODUCTION METHOD THEREOFOctober 2021January 2026Allow5131NoNo
17600678Antifungal CompositionsOctober 2021July 2025Allow4531NoNo
17474322SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTSeptember 2021January 2024Allow2820NoNo
17433906COATING COMPOSITION FOR SEEDAugust 2021April 2025Abandon4311NoNo
17401777HYPOCHLOROUS ACID-BASED EYELID CLEANSERSAugust 2021August 2023Allow2420NoNo
17389917METHODS OF DYEING KERATIN FIBERS WITH A PIGMENT DYEING COMPOSITIONJuly 2021July 2024Allow3620YesNo
17427082COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING GROWTH FACTORJuly 2021January 2025Abandon4211NoNo
17384227COLON CLEANSING COMPOSITIONS AND METHOD OF USEJuly 2021May 2024Allow3330YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JUSTICE, GINA CHIEUN YU.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
58
Examiner Affirmed
47
(81.0%)
Examiner Reversed
11
(19.0%)
Reversal Percentile
30.6%
Lower than average

What This Means

With a 19.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
210
Allowed After Appeal Filing
32
(15.2%)
Not Allowed After Appeal Filing
178
(84.8%)
Filing Benefit Percentile
18.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner JUSTICE, GINA CHIEUN YU - Prosecution Strategy Guide

Executive Summary

Examiner JUSTICE, GINA CHIEUN YU works in Art Unit 1617 and has examined 1,100 patent applications in our dataset. With an allowance rate of 50.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner JUSTICE, GINA CHIEUN YU's allowance rate of 50.4% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JUSTICE, GINA CHIEUN YU receive 2.51 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JUSTICE, GINA CHIEUN YU is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -5.7% benefit to allowance rate for applications examined by JUSTICE, GINA CHIEUN YU. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.3% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 34.9% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 87.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 58.0% of appeals filed. This is in the 32% percentile among all examiners. Of these withdrawals, 58.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.7% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.7% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.